Greenwich LifeSciences, Inc. (NASDAQ: GLSI) announced that an abstract has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 28 to June 2, 2026. The abstract, co‑authored by the company and the FLAMINGO‑01 Steering Committee, will present preliminary injection‑site reaction immune‑response data from the non‑HLA‑A*02 open‑label arm of the Phase III trial. The abstract will be available on June 1, 2026, the day of the presentation, and will accompany a poster presentation at the conference.
The acceptance marks a key milestone in GLSI’s clinical development program. The FLAMINGO‑01 trial is evaluating GLSI‑100, an immunotherapy designed to prevent breast cancer recurrence in HER2‑positive patients. Early data from the non‑HLA‑A*02 arm show an approximately 80% reduction in recurrence rates after the primary immunization series, a result that aligns with Phase IIb findings and suggests strong efficacy potential.
Injection‑site reactions (ISRs) are a common adverse event in the Phase IIb study and serve as a surrogate for immune activation, correlating with delayed‑type hypersensitivity (DTH) tests. Preliminary ISR data presented at the AACR 2026 meeting indicated a significant increase in DTH responses following GLSI‑100 treatment, reinforcing the immunogenicity signal that the ASCO abstract will further explore.
In addition to the scientific milestone, GLSI received a Nasdaq notice on April 16, 2026 for late filing of its Form 10‑K for the fiscal year ended December 31, 2025. The notice does not affect the company’s listing status. As of March 31, 2026, GLSI reported a cash balance of approximately $10.5 million, supported by an at‑the‑market financing facility that has exceeded the company’s Q1 2026 cash burn rate.
CEO Snehal Patel said, "We look forward to meeting many of our principal investigators at the conference. Our abstract will be the second abstract co‑authored by the Company and the full Steering Committee of FLAMINGO‑01 presenting preliminary injection site reaction immune response data from the non‑HLA‑A*02 open‑label arm." The abstract’s presentation at ASCO provides a formal venue for GLSI to share early safety and immunogenicity findings with the oncology community and to set the stage for subsequent data releases and regulatory engagement.
revised_sentiment_rating
}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.